Federated Hermes, Inc. Cerevel Therapeutics Holdings, Inc. Transaction History

Federated Hermes, Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$23.9 - $35.38 $17 Million - $25.1 Million	-710,000 Reduced 36.88%	1,214,972 $38.6 Million
Q1 2023 May 08, 2023	SELL	$22.82 - $35.32 $21.5 Million - $33.3 Million	-942,479 Reduced 32.87%	1,924,972 $47 Million
Q4 2022 Feb 13, 2023	SELL	$25.35 - $31.96 $11.3 Million - $14.3 Million	-445,882 Reduced 13.46%	2,867,451 $90.4 Million
Q3 2022 Nov 14, 2022	BUY	$25.5 - $41.42 $5.1 Million - $8.28 Million	200,000 Added 6.42%	3,313,333 $93.6 Million
Q3 2021 Nov 15, 2021	BUY	$21.26 - $38.85 $24.7 Million - $45.2 Million	1,163,333 Added 59.66%	3,113,333 $91.8 Million
Q1 2021 May 13, 2021	BUY	$12.37 - $17.74 $12.3 Million - $17.7 Million	998,300 Added 104.9%	1,950,000 $26.8 Million
Q4 2020 Feb 12, 2021	BUY	$9.82 - $18.27 $9.35 Million - $17.4 Million	951,700 New	951,700 $15.8 Million

242

154M

2.19M

3.87M

Ticker CERE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 155,752,000
Description
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

Stay updated on Federated Hermes, Inc. with notifications on news.